Janux Therapeutics, Inc. (JANX)
18.15
+0.33
(+1.85%)
USD |
NASDAQ |
Nov 04, 15:40
Janux Therapeutics Enterprise Value : 138.49M for Nov. 3, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 03, 2026 | 138.49M |
| November 02, 2026 | 116.50M |
| October 30, 2026 | 117.11M |
| October 29, 2026 | 139.10M |
| October 28, 2026 | 152.53M |
| October 27, 2026 | 104.28M |
| October 26, 2026 | 69.47M |
| October 23, 2026 | 67.64M |
| October 22, 2026 | 92.07M |
| October 21, 2026 | 84.13M |
| October 20, 2026 | 100.62M |
| October 19, 2026 | 72.52M |
| October 16, 2026 | 58.47M |
| October 15, 2026 | 107.95M |
| October 14, 2026 | 96.34M |
| October 13, 2026 | 99.40M |
| October 12, 2026 | 158.64M |
| October 09, 2026 | 173.30M |
| October 08, 2026 | 180.02M |
| October 07, 2026 | 144.59M |
| October 06, 2026 | 75.58M |
| October 05, 2026 | 60.31M |
| October 02, 2026 | 84.13M |
| October 01, 2026 | 85.96M |
| September 30, 2026 | 105.50M |
| Date | Value |
|---|---|
| September 29, 2026 | 85.35M |
| September 28, 2026 | 62.75M |
| September 25, 2026 | 45.65M |
| September 24, 2026 | 68.86M |
| September 23, 2026 | 59.09M |
| September 22, 2026 | 117.11M |
| September 21, 2026 | 89.01M |
| September 18, 2026 | 63.36M |
| September 17, 2026 | 79.85M |
| September 16, 2026 | 42.29M |
| September 15, 2026 | 54.20M |
| September 14, 2026 | 107.34M |
| September 11, 2026 | 94.51M |
| September 10, 2026 | 129.94M |
| September 09, 2026 | 230.71M |
| September 08, 2026 | 274.08M |
| September 04, 2026 | 286.30M |
| September 03, 2026 | 259.42M |
| September 02, 2026 | 253.31M |
| September 01, 2026 | 203.84M |
| August 31, 2026 | 162.92M |
| August 28, 2026 | 151.31M |
| August 27, 2026 | 197.12M |
| August 26, 2026 | 203.84M |
| August 25, 2026 | 191.01M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Iovance Biotherapeutics, Inc. | 3.748B |
| Agenus, Inc. | 548.91M |
| Amgen, Inc. | 292.67B |
| Anika Therapeutics, Inc. | 247.14M |
| BioCryst Pharmaceuticals, Inc. | 2.671B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -21.97M |
| Revenue (Quarterly) | 10.27M |
| Total Expenses (Quarterly) | 32.24M |
| EPS Diluted (Quarterly) | -0.3491 |
| Gross Profit Margin (Quarterly) | 95.49% |
| Profit Margin (Quarterly) | -214.0% |
| Earnings Yield | -9.06% |
| Normalized Earnings Yield | -9.057 |